PURPOSE: The purpose of the study is to (1) estimate the direction, clinical relevance, and duration of health-related quality-of-life (HRQL) change in the first year following esophageal cancer surgery and (2) to assess the robustness of the estimates by subgroup and sensitivity analyses, and an exploration of publication bias. METHODS: A systematic literature search in MEDLINE, EMBASE, CINAHL, PsychINFO, and CENTRAL to identify randomized and non-randomized studies was performed. We compared the baseline HRQL data with 3-, 6-, 9-, or 12-month follow-ups to estimate the magnitude and duration of HRQL change. These estimates were then classified as trivial, small, medium, or large. Primary outcomes were role functioning, eating, and fatigue. Secondary outcomes were physical and social functioning, dysphagia, pain, and coughing problems. We conducted subgroup analysis for open surgery, open surgery preceded by neoadjuvant therapy, and minimally invasive surgery. Sensitivity analyses assessed the influence of study design, transformation/imputation of the data, and HRQL questionnaire used. RESULTS: We included the data from 15 studies to estimate the change in 28 HRQL outcomes after esophageal cancer surgery. The main analysis showed that patients' social functioning deteriorated. Symptoms of fatigue, pain, and coughing problems increased. These changes lasted for 9-12 months, although some symptoms persisted beyond the first year after surgery. For many other HRQL outcomes, estimates were only robust after subgroup or sensitivity analyses (e.g., role and physical functioning), or remained too heterogeneous to interpret (e.g., eating and dysphagia). CONCLUSIONS: Patients will experience a clinically relevant and long-lasting deterioration in HRQL after esophageal cancer surgery. However, for many HRQL outcomes, more and better quality evidence is needed.
PURPOSE: The purpose of the study is to (1) estimate the direction, clinical relevance, and duration of health-related quality-of-life (HRQL) change in the first year following esophageal cancer surgery and (2) to assess the robustness of the estimates by subgroup and sensitivity analyses, and an exploration of publication bias. METHODS: A systematic literature search in MEDLINE, EMBASE, CINAHL, PsychINFO, and CENTRAL to identify randomized and non-randomized studies was performed. We compared the baseline HRQL data with 3-, 6-, 9-, or 12-month follow-ups to estimate the magnitude and duration of HRQL change. These estimates were then classified as trivial, small, medium, or large. Primary outcomes were role functioning, eating, and fatigue. Secondary outcomes were physical and social functioning, dysphagia, pain, and coughing problems. We conducted subgroup analysis for open surgery, open surgery preceded by neoadjuvant therapy, and minimally invasive surgery. Sensitivity analyses assessed the influence of study design, transformation/imputation of the data, and HRQL questionnaire used. RESULTS: We included the data from 15 studies to estimate the change in 28 HRQL outcomes after esophageal cancer surgery. The main analysis showed that patients' social functioning deteriorated. Symptoms of fatigue, pain, and coughing problems increased. These changes lasted for 9-12 months, although some symptoms persisted beyond the first year after surgery. For many other HRQL outcomes, estimates were only robust after subgroup or sensitivity analyses (e.g., role and physical functioning), or remained too heterogeneous to interpret (e.g., eating and dysphagia). CONCLUSIONS: Patients will experience a clinically relevant and long-lasting deterioration in HRQL after esophageal cancer surgery. However, for many HRQL outcomes, more and better quality evidence is needed.
Authors: Inge Henselmans; Marc Jacobs; Mark I van Berge Henegouwen; Hanneke C J M de Haes; Mirjam A G Sprangers; Ellen M A Smets Journal: Patient Educ Couns Date: 2012-01-14
Authors: Katrin M Sjoquist; Bryan H Burmeister; B Mark Smithers; John R Zalcberg; R John Simes; Andrew Barbour; Val Gebski Journal: Lancet Oncol Date: 2011-06-16 Impact factor: 41.316
Authors: John T Maringwa; Chantal Quinten; Madeleine King; Jolie Ringash; David Osoba; Corneel Coens; Francesca Martinelli; Jurgen Vercauteren; Charles S Cleeland; Henning Flechtner; Carolyn Gotay; Eva Greimel; Martin J Taphoorn; Bryce B Reeve; Joseph Schmucker-Von Koch; Joachim Weis; Egbert F Smit; Jan P van Meerbeeck; Andrew Bottomley Journal: Support Care Cancer Date: 2010-10-01 Impact factor: 3.603
Authors: Marc Jacobs; Rhiannon C Macefield; Jane M Blazeby; Ida J Korfage; Mark I van Berge Henegouwen; Hanneke C J M de Haes; Ellen M Smets; Mirjam A G Sprangers Journal: Qual Life Res Date: 2012-10-20 Impact factor: 4.147
Authors: Allen C Sherman; Thomas V Merluzzi; James E Pustejovsky; Crystal L Park; Login George; George Fitchett; Heather S L Jim; Alexis R Munoz; Suzanne C Danhauer; Mallory A Snyder; John M Salsman Journal: Cancer Date: 2015-08-10 Impact factor: 6.860
Authors: J Rees; C N Hurt; S Gollins; S Mukherjee; T Maughan; S J Falk; J Staffurth; R Ray; N Bashir; J I Geh; D Cunningham; R Roy; J Bridgewater; G Griffiths; L S Nixon; J M Blazeby; T Crosby Journal: Br J Cancer Date: 2015-07-23 Impact factor: 7.640
Authors: N Haj Mohammad; A W Walter; M G H van Oijen; M C C M Hulshof; J J G H M Bergman; M C J Anderegg; M I van Berge Henegouwen; I Henselmans; M A G Sprangers; H W M van Laarhoven Journal: Support Care Cancer Date: 2015-04-18 Impact factor: 3.603
Authors: Derek Alderson; David Cunningham; Matthew Nankivell; Jane M Blazeby; S Michael Griffin; Adrian Crellin; Heike I Grabsch; Rupert Langer; Susan Pritchard; Alicia Okines; Richard Krysztopik; Fareeda Coxon; Joyce Thompson; Stephen Falk; Clare Robb; Sally Stenning; Ruth E Langley Journal: Lancet Oncol Date: 2017-08-04 Impact factor: 41.316